Business
Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
EMERYVILLE, Calif., December 15, 2025--OmniAb, Inc. (NASDAQ: OABI) announces the launch of its new OmniUltra™ platform, the industry’s first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego.
About this update from Omniab, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":407,"url":"https://media.zenfs.com/en/business-wire.com/5099f68e759e1500d17841e40bf6057c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GtMnjwyYh69h2ewySCNMtw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTgxNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5099f68e759e1500d17841e40bf6057c","width":480,"height":407}},"lazy":false},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/9af5cb1929ce39d9fd4f943ad14a514d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hEKwRSETC0DmQ7aEWER0.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9af5cb1929ce39d9fd4f943ad14a514d","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/5T_NitukIkb_ZSSAfttFkA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/9af5cb1929ce39d9fd4f943ad14a514d","width":1024,"height":512}}},{"type":"text","content":"First and only transgenic chicken platform engineered to express ultralong CDRH3 domains on a human antibody framework broadens therapeutic opportunities beyond conventional antibodies","length":184,"tagName":"p","attribs":{}},{"type":"text","content":"OmniUltra Virtual Investor Event begins at 5:00 p.m. Eastern time today","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"EMERYVILLE, Calif., December 15, 2025--(BUSINESS WIRE)--OmniAb, Inc. (NASDAQ: OABI) announces the launch of its new OmniUltra™ platform, the industry’s first and only transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics (AET) Conference underway in San Diego.","length":354,"tagName":"p"},{"type":"text","content":"OmniUltra is a versatile in vivo discovery platform that extends beyond traditional antibody modalities into the peptide space, enabling multiple therapeutic applications. It generates naturally optimized human immune antibody repertoires featuring cow-inspired ultralong CDRH3 domains, unlocking novel binding modes and access to ...